Xeris Biopharma (NASDAQ:XERS) Stock: Insider Kevin Mcculloch Sells 15,000 Shares

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) insider Kevin McCulloch sold 15,000 shares of the firm’s stock in a transaction on Monday, November 2nd. The stock was sold at an average price of $10.23, for a total value of $153,450.00. Following the completion of the sale, the insider directly owned 1,584,208 shares of the company’s stock, valued at $16,206,447.84. This trade represents a 0.94% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Kevin Mcculloch also recently made the following trade(s):

• On Thursday, October 1st, Kevin McCulloch sold 15,000 shares of Xeris Biopharma stock. The shares were sold at an average price of $9.41, for a total transaction of $141,150.00.
• On Monday, September 28th, Kevin McCulloch sold 25,000 shares of Xeris Biopharma stock. The stock was sold at an average price of $10.00, for a total transaction of $250,000.00.
• On Tuesday, September 1st, Kevin McCulloch sold 15,000 shares of Xeris Biopharma stock. The stock was sold at an average price of $8.49, for a total transaction of $127,350.00.

Xeris Biopharma Trading Up 1.1%

XERS stock traded up $0.11 during trading on Wednesday, reaching $10.46. 3,142,009 shares of the stock were exchanged, compared to its average volume of 2,030,196. The company has a current ratio of 1.45, a quick ratio of 1.02 and a debt-to-equity ratio of 17.00. The firm has a market capitalization of $1.91 billion, a price-to-earnings ratio of -95.09 and a beta of 0.61. The business has a 50 day moving average price of $9.37 and a 200-day moving average price of $7.54. Xeris Biopharma Holdings, Inc. has a 1 year low of $5.25 and a 1 year high of $11.41.

Xeris Biopharma (NASDAQ:XERS) last posted its quarterly earnings results on Thursday, August 6th. The company reported ($0.18) earnings per share for the quarter, missing the consensus estimate of $0.01 by ($0.19). The firm had revenue of $92.10 million during the quarter, compared to analysts’ expectations of $90.12 million. Xeris Biopharma had a negative net margin of 5.12% and a positive return on equity of 338.21%. On average, research analysts predict that Xeris Biopharma Holdings, Inc. will post 0.07 earnings per share for the current year.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in XERS. GK Wealth Management LLC purchased a new position in shares of Xeris Biopharma during the third quarter worth $32,000. Allworth Financial LP purchased a new stake in shares of Xeris Biopharma in the 2nd quarter valued at $34,000. KBC Group NV purchased a new stake in shares of Xeris Biopharma in the 1st quarter valued at $27,000. William Mack & Associates Inc. acquired a new position in Xeris Biopharma during the 3rd quarter worth about $53,000. Finally, Sterling Capital Management LLC lifted its stake in Xeris Biopharma by 848.0% during the 3rd quarter. Sterling Capital Management LLC now owns 5,707 shares of the company’s stock worth $55,000 after acquiring an additional 5,105 shares in the last quarter. 42.75% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on the company. Weiss Ratings downgraded Xeris Biopharma from a “hold (c-)” rating to a “sell (d-)” rating in a research report on Tuesday, August 11th. Leerink Partners upped their target price on shares of Xeris Biopharma from $12.00 to $16.00 and gave the company an “outperform” rating in a research report on Thursday, September 10th. Barclays increased their target price on shares of Xeris Biopharma from $12.00 to $14.00 and gave the stock an “overweight” rating in a research note on Tuesday, October 6th. Finally, Wall Street Zen upgraded shares of Xeris Biopharma from a “hold” rating to a “buy” rating in a research report on Saturday, September 19th. Four investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $13.20.

About Xeris Biopharma

Xeris Biopharma, Inc is a specialty pharmaceutical company focused on developing and commercializing therapies for patients with endocrinology, gastroenterology and other serious or chronic conditions. The company uses proprietary formulation and delivery technologies designed to make complex therapies more stable, convenient and suitable for self-administration.

Xeris’ commercial portfolio includes Gvoke, a ready-to-use glucagon injection for the treatment of severe hypoglycemia in adults and children with diabetes; Recorlev (levoketoconazole), an oral therapy for endogenous hypercortisolemia associated with endogenous Cushing’s syndrome; and Keveyis (dichlorphenamide), a treatment for primary periodic paralysis.